Drug
JNJ-56136379 clinical trials
Also written JNJ-56136379 and JNJ-6379.
- studies test it
- 12
- open now
- 0
- in phase 3
- 0
- first study started
- 2015
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Janssen Sciences Ireland UC (7) · Janssen Research & Development, LLC (5)
Often tested with
Tested in the same studies.
Daplusiran (3) · Tomligisiran (3) · Itraconazole (1) · Drospirenone (1) · Ethinyl Estradiol (1) · Midazolam (1) · Bictegravir (1) · Emtricitabine (1)
Studies
Open first, then newest update. How each study uses JNJ-56136379 is read from its arms, and is right about nine times in ten.
Testing it · 12
- A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04439539Written as JNJ-56136379
- A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Research & Development, LLCNCT04585789Written as JNJ-56136379
- A Study of Different Combination Regimens Including JNJ-73763989 and/or JNJ-56136379 for the Treatment of Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT03982186Written as JNJ-56136379
- A Study of JNJ 73763989+JNJ 56136379+Nucleos(t)Ide Analog (NA) Regimen Compared to NA Alone in e Antigen Negative Virologically Suppressed Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT04129554Written as JNJ-56136379
- A Study to Evaluate the Effect of Itraconazole on JNJ-56136379 in Healthy Adult ParticipantsCompletedPhase 1Janssen Sciences Ireland UCNCT03945539Written as JNJ-56136379
- A Study of Orally Administered JNJ-56136379 to Evaluate Safety, Tolerability and Pharmacokinetics After Single Ascending Doses and One Multiple Dose Regimen in Healthy Participants (Part I), and After Multiple Dose Regimens in Participants With Chronic Hepatitis B (Part II)CompletedPhase 1Janssen Sciences Ireland UCNCT02662712Written as JNJ-56136379
- An Efficacy, Safety, and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus InfectionCompletedPhase 2Janssen Sciences Ireland UCNCT03361956Written as JNJ-56136379
- A Study to Evaluate the Effect of Renal Impairment on JNJ-56136379 in Adult ParticipantsTerminatedPhase 1Janssen Research & Development, LLCNCT04474210Written as JNJ-56136379
- A Study of JNJ-56136379 in Healthy ParticipantsWithdrawnPhase 1Janssen Research & Development, LLCNCT04853524Written as JNJ-56136379
- A Study to Evaluate the Effect of Hepatic Impairment on JNJ-56136379CompletedPhase 1Janssen Sciences Ireland UCNCT04208399Written as JNJ-56136379
- A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ-56136379 in Healthy Japanese Adult ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT02933580Written as JNJ-56136379
- A Study in Healthy Female Participants to Investigate the Effect of JNJ-56136379 at Steady-state on the Single-dose Pharmacokinetics of Ethinylestradiol and Drospirenone (Oral Contraceptive) and on the Single-dose Pharmacokinetics of Midazolam (Probe Substrate for Cytochrome P450 3A4)CompletedPhase 1Janssen Sciences Ireland UCNCT03111511Written as JNJ-56136379
Given in every arm · 1 — JNJ-56136379 is usual care beside what is tested
Codes
What other systems call JNJ-56136379 · ClinicalTrials.gg INT001597
- MeSH (NLM) C000716080JNJ-56136379One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000716080 | JNJ-56136379 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.